New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
11:58 EDTILMN, TMONew China rule prompts BGI to suspend trisomy testing, GenomeWeb says
BGI said a recent announcement from Chinese officials that genetic tests should be regulated has prompted the company to work with its collaborators to suspend the clinical application of its non-invasive fetal trisomy test in mainland China, according to GenomeWeb. Other providers of sequencing-based trisomy testing products, including Illumina (ILMN) and Thermo Fisher-owned (TMO) Life Technologies, declined to comment on the regulation notice, the report stated. The Fly notes that Illumina announced in January of 2010 that BGI had purchased 128 HiSeq 2000 sequencing systems. Illumina said at that time that revenue related to the sale of those instruments was expected to be recognized over the next three years. Reference Link
News For ILMN;TMO From The Last 14 Days
Check below for free stories on ILMN;TMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 30, 2014
08:55 EDTTMOThermo Fisher could rise 20% in next 12 months, Barron's says
Subscribe for More Information
August 21, 2014
05:42 EDTILMNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
10:04 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:18 EDTILMNIllumina upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
August 19, 2014
11:32 EDTILMNLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use